NDC 82983-403-01 - Potassium Chloride for Oral Solution
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 82983-403
- Requested NDC
- 82983-403-01
- Package NDCs from labels
- 82983-403-01, 82983-403-30, 82983-403-10
- Manufacturer
- Ajenat Pharmaceuticals LLC
- Effective date
- 2025-12-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Potassium Chloride for Oral Solution - Ajenat Pharmaceuticals LLC | Ajenat Pharmaceuticals LLC | 2025-12-29 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82983-403-01 | Potassium Chloride for Oral Solution | 1.58 g in 1 POUCH | POWDER, FOR SOLUTION | 1.58 | 6 | |
| 82983-403-10 | Potassium Chloride for Oral Solution | 100 in 1 CARTON | POWDER, FOR SOLUTION | 100 | 6 | |
| 82983-403-30 | Potassium Chloride for Oral Solution | 30 in 1 CARTON | POWDER, FOR SOLUTION | 30 | 6 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 82983-403-01 | EA - Each | 82983-403 | c6649ee7-7baa-41ec-9e1d-eb4e69aa4730 | 1 | 2026-01-08 |
| 82983-403-10 | EA - Each | 82983-403 | e72cb457-d97a-4256-8d8b-c330d1770675 | 1 | 2026-01-08 |
| 82983-403-30 | EA - Each | 82983-403 | 491b8085-fdb3-4f3a-a298-f0a460c93634 | 1 | 2026-01-08 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Supreme | ABROTANUM, ANACARDIUM ORIENTALE, ARSENICUM ALBUM, BARYTA MURIATICA, HELLEBORUS NIGER, IGNATIA AMARA, LYCOPODIUM CLAVATUM, NICOTINAMIDUM, SECALE CORNUTUM, THYMUS (BOVINE), THYROIDINUM (BOVINE), CALCAREA CARBONICA, CALCAREA PHOSPHORICA, HYPOTHALAMUS SUIS, PITUITARUM POSTERIUM (BOVINE), SILICEA | BOUARI GROUP, LLC dba WEIGHT LOSS COMPANY, THE | 72c4679b-aa97-4888-9178-581d0f99c0b6 | 2020-09-11 | Warnings | ETJ7Z6XBU4 |
| POTASSIUM CHLORIDE IN DEXTROSE | DEXTROSE AND POTASSIUM CHLORIDE | B. Braun Medical Inc. | e5bbb3e1-ab50-4ec7-a2b4-ce4091712e23 | 2020-07-31 | Warnings, Adverse reactions | 660YQ98I10 |
| Cardioplegic | CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE AND SODIUM CHLORIDE | Baxter Healthcare Corporation | 1fd50ce5-2799-4c26-81da-02cf0578dd9e | 2020-06-11 | Warnings, Adverse reactions | 660YQ98I10 |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | XF417D3PSL | |
| LACTATED RINGERS AND DEXTROSE | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, AND DEXTROSE MONOHYDRATE | HF Acquisition Co LLC, DBA HealthFirst | a62cf623-9b8a-37e0-e053-2995a90add5b | 2020-05-21 | Warnings, Adverse reactions | 660YQ98I10 |
| Isolyte S | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | B. Braun Medical Inc. | 7e8fe27f-ff82-48c1-9bf6-3c589c8e985d | 2020-05-14 | Warnings, Adverse reactions | 660YQ98I10 |
| Potassium Chloride | POTASSIUM CHLORIDE | Genus Lifesciences Inc. | 23d818e7-c076-40de-8dc1-0b51ba4be96a | 2020-04-28 | Warnings, Adverse reactions | 1867544 660YQ98I10 |
| Potassium Chloride | POTASSIUM CHLORIDE | Lupin Pharmaceuticals,Inc. | 1bbacdbb-91fa-4897-a00c-1b293de27b83 | 2020-04-27 | Warnings, Adverse reactions | 1867544 660YQ98I10 |
| Potassium Chloride | POTASSIUM CHLORIDE | Mylan Pharmaceuticals Inc. | c64ed4c0-1e27-42b3-9625-fb4e0d31e271 | 2020-04-15 | Warnings, Adverse reactions | 660YQ98I10 |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 660YQ98I10 |
| Renacidin | CITRIC ACID, GLUCONOLACTONE AND MAGNESIUM CARBONATE | United-Guardian, Inc. | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 | 2019-12-17 | Warnings, Adverse reactions | XF417D3PSL |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | XF417D3PSL | |
| Plasma-Lyte A | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDE | Baxter Healthcare Corporation | 6ec9e61c-2c26-402f-8604-f446b2e34058 | 2019-08-05 | Warnings, Adverse reactions | 660YQ98I10 |
| Potassium Chloride in Dextrose | POTASSIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 45de5402-5e61-4bbd-8bbc-5e3392c9920e | 2019-07-15 | Warnings, Adverse reactions | 660YQ98I10 |
| Potassium Chloride | POTASSIUM CHLORIDE | BluePoint Laboratories | 431ff2ef-567c-4b60-af43-f4da61febaad | 2019-07-03 | Warnings, Adverse reactions | 660YQ98I10 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.